Magle Chemoswed Holding AB
STO:MAGLE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.6
46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Magle Chemoswed Holding AB
PP&E Net
Magle Chemoswed Holding AB
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
PP&E Net
kr107m
|
CAGR 3-Years
1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
PP&E Net
kr1.1B
|
CAGR 3-Years
34%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
PP&E Net
kr727.4m
|
CAGR 3-Years
76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
PP&E Net
kr313m
|
CAGR 3-Years
36%
|
CAGR 5-Years
23%
|
CAGR 10-Years
22%
|
|
|
G
|
Genovis AB
STO:GENO
|
PP&E Net
kr91.4m
|
CAGR 3-Years
100%
|
CAGR 5-Years
66%
|
CAGR 10-Years
44%
|
|
|
MedCap AB (publ)
STO:MCAP
|
PP&E Net
kr382.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
31%
|
|
Magle Chemoswed Holding AB
Glance View
Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
See Also
What is Magle Chemoswed Holding AB's PP&E Net?
PP&E Net
107m
SEK
Based on the financial report for Dec 31, 2023, Magle Chemoswed Holding AB's PP&E Net amounts to 107m SEK.
What is Magle Chemoswed Holding AB's PP&E Net growth rate?
PP&E Net CAGR 5Y
12%
Over the last year, the PP&E Net growth was 6%. The average annual PP&E Net growth rates for Magle Chemoswed Holding AB have been 1% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
